Anti-EpoR Antibody Blocks Epo-Induced [Ca2+]i Increase
| F350/F380 . | ||||
|---|---|---|---|---|
| Pretreatment . | Baseline . | Peak . | % Increase . | N . |
| IMDM | 0.38 ± 0.02 | 0.70 ± 0.07* | 185 ± 16 | 11 |
| Anti-EpoR antibody | 0.41 ± 0.02 | 0.42 ± 0.02 | 102 ± 1 | 14 |
| Mouse IgG | 0.39 ± 0.01 | 0.69 ± 0.10* | 175 ± 22 | 9 |
| F350/F380 . | ||||
|---|---|---|---|---|
| Pretreatment . | Baseline . | Peak . | % Increase . | N . |
| IMDM | 0.38 ± 0.02 | 0.70 ± 0.07* | 185 ± 16 | 11 |
| Anti-EpoR antibody | 0.41 ± 0.02 | 0.42 ± 0.02 | 102 ± 1 | 14 |
| Mouse IgG | 0.39 ± 0.01 | 0.69 ± 0.10* | 175 ± 22 | 9 |
Human day 10 BFU-E derived cells on coverslips were exposed to IMDM, anti-EpoR antibody (10 μg/mL), or mouse IgG (10 μg/mL) for 3 hours and during the 20 minutes of fura-2 loading. They were then washed with PBS and fluorescence intensity ratios (F350/F380) were measured with digital video imaging before and at 1, 5, 10, 15, and 20 minutes after Epo (2 U/mL) addition (Materials and Methods). Results are expressed as mean ± SE for baseline or peak F350/F380 or % increase above baseline.
Abbreviation: N, number of observations.
P < .05 compared with baseline.